Additionally, NDC-011, a novel drug combination developed through DR.NOAH's AI-based drug discovery platform, received Orphan Drug Designation (ODD) from the U.S. FDA in 2023 and IND approval for a ...

Fintel reports that on December 9, 2025, B of A Securities maintained coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a Buy recommendation. Analyst Price Forecast Suggests 5.02% Upside As of ...

BofA analyst Jason Gerberry raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $97 from $86 and keeps a Buy rating on the shares ...

If you are wondering whether Ionis Pharmaceuticals is still a smart buy after its big run, or if most of the upside is already reflected in the price, you are not alone. That is exactly what we are ...

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well ...

Bristol Myers Squibb said it will enroll more patients in a key Phase 3 trial studying its drug Cobenfy in psychosis associated with Alzheimer’s disease, after the company found “irregularities due to ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Phase 3 data could make the Dutch biotech's drug competitive in the increasingly crowded market of hereditary angioedema treatments.

Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted ...

The dynamics of the geographic atrophy market are expected to change in the coming years due to the rising global prevalence driven by aging populations, demand for disease-modifying interventions, ...

Ionis Pharmaceuticals (IONS) caught investor attention after announcing its investigational drug olezarsen earned Breakthrough Therapy designation from the FDA for severe hypertriglyceridemia. The ...